Syntegra Private Wealth Group LLC Sells 40 Shares of Amgen Inc. (NASDAQ:AMGN)

Syntegra Private Wealth Group LLC lessened its position in Amgen Inc. (NASDAQ:AMGN) by 3.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,168 shares of the medical research company’s stock after selling 40 shares during the quarter. Syntegra Private Wealth Group LLC’s holdings in Amgen were worth $304,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AMF Tjanstepension AB grew its position in Amgen by 16.9% in the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after purchasing an additional 17,387 shares during the last quarter. Czech National Bank grew its position in Amgen by 7.1% during the third quarter. Czech National Bank now owns 109,459 shares of the medical research company’s stock worth $35,269,000 after buying an additional 7,237 shares in the last quarter. City Center Advisors LLC bought a new position in Amgen during the third quarter valued at about $220,000. Atomi Financial Group Inc. increased its stake in Amgen by 4.2% during the third quarter. Atomi Financial Group Inc. now owns 5,388 shares of the medical research company’s stock valued at $1,736,000 after acquiring an additional 217 shares during the period. Finally, City Holding Co. raised its holdings in Amgen by 0.6% in the 3rd quarter. City Holding Co. now owns 10,719 shares of the medical research company’s stock valued at $3,454,000 after acquiring an additional 67 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on AMGN shares. Citigroup lowered their price target on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company lowered their target price on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research note on Friday, January 10th. Wolfe Research assumed coverage on shares of Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. UBS Group lowered their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Finally, Bank of America restated an “underperform” rating and set a $256.00 target price on shares of Amgen in a research report on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $314.00.

Amgen Trading Up 6.5 %

AMGN opened at $307.81 on Thursday. The stock has a market capitalization of $165.46 billion, a P/E ratio of 39.41, a P/E/G ratio of 2.87 and a beta of 0.56. The firm’s fifty day simple moving average is $271.14 and its 200 day simple moving average is $303.52. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%. As a group, research analysts anticipate that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.09%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.